White Matter Hyperintensities in Aging and Dementia
Phase of Trial: Phase IV
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Florbetaben F18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use; Pharmacodynamics
- 11 Sep 2019 Status changed from recruiting to completed.
- 04 Apr 2019 Planned number of patients changed from 20 to 50.
- 04 Apr 2019 Planned End Date changed from 1 Nov 2019 to 31 Aug 2019.